KERIM KAYLAN, MD, PHD
Endocrinology, Diabetes & Metabolism Physician in CHICAGO, Illinois. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
KERIM KAYLAN, MD, PHD filed 866 Medicare Part D claims in 2023 as a Endocrinology, Diabetes & Metabolism Physician in CHICAGO, Illinois, prescribing 77% generic.
- 866
- Part D claims, 2023
- 77%
- generic prescribing
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
KERIM KAYLAN, MD, PHD's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
866 Top 27% higher than 73% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
KERIM KAYLAN, MD, PHD practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about KERIM KAYLAN, MD, PHD?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Illinois
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Illinois providers
Endocrinology, Diabetes & Metabolism Physician share within Illinois
Endocrinology, Diabetes & Metabolism Physician is one of the more visible NUCC categories in Illinois
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Endocrinology, Diabetes & Metabolism Physician ABMS/AOA estimate
Est. board-certified rate (Endocrinology, Diabetes & Metabolism Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
Specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
KERIM KAYLAN, MD, PHD appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding MD, PHD credentials at 5841 S. MARYLAND AVE. M/C 1027, CHICAGO, IL, 60637, with a listed phone of (773) 702-6138. NPI 1710513122 was issued on 03/17/2020. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what KAYLAN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 866 prescription claims written by this provider, covering 106 Medicare beneficiaries and totaling roughly $205K in drug spend, split 23% brand-name and 77% generic by claim count, with an opioid prescribing rate of 1.5%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1710513122 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | MD, PHD |
| Gender | Male |
| NPI Issued | 03/17/2020 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm KERIM KAYLAN, MD, PHD's current license status, disciplinary history, and board certifications with the Illinois Department of Financial and Professional Regulation in Illinois before relying on this page for a clinical or care decision.
How we sourced this profile
License & disciplinary context — Illinois IDFPR 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~42K Illinois medical licensees in 2023 — they are NOT specific to KERIM KAYLAN, MD, PHD. To verify KERIM KAYLAN, MD, PHD's current license status, search the IDFPR public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
IDFPR publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Illinois disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
23% brand-name claims vs 77% generic, on 866 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,894
- Total Day Supply
- 55,430
- Brand vs Generic
- 23% brand / 77% generic
- Brand Drug Cost
- $185K
- Generic Drug Cost
- $20K
- Opioid Claims
- 13 (1.5% rate)
Patient Demographics
- Average Patient Age
- 69.7 years
- Avg HCC Risk Score
- 1.98
- Gender Split
- 70% female / 30% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What KERIM KAYLAN, MD, PHD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Atorvastatin Calcium
Atorvastatin Calcium
82 claims
- Amlodipine Besylate
Amlodipine Besylate
60 claims
- Lisinopril 31
Lisinopril
31 claims
- Metformin Hcl 31
Metformin Hcl
31 claims
- Furosemide 26
Furosemide
26 claims
- Gabapentin 22
Gabapentin
22 claims
- Enalapril Maleate 19
Enalapril Maleate
19 claims
- Metformin Hcl Er 17
Metformin Hcl Er
17 claims
| Drug | Claims |
|---|---|
| Atorvastatin Calcium | 82 |
| Amlodipine Besylate | 60 |
| Lisinopril | 31 |
| Metformin Hcl | 31 |
| Furosemide | 26 |
| Gabapentin | 22 |
| Enalapril Maleate | 19 |
| Metformin Hcl Er Metformin Hcl | 17 |
| Spironolactone | 17 |
| Omeprazole | 16 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How KERIM KAYLAN, MD, PHD fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
KERIM KAYLAN, MD, PHD's 866 claims are below the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Illinois
Other clinicians with the same primary specialty enrolled in Illinois, drawn from the same CMS NPPES roster as KAYLAN.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Illinois
Frequently Asked Questions
What is KERIM KAYLAN, MD, PHD's specialty? ▼
How much does KERIM KAYLAN, MD, PHD prescribe under Medicare Part D? ▼
Where is KERIM KAYLAN, MD, PHD located? ▼
What is KERIM KAYLAN, MD, PHD's NPI number? ▼
Does KERIM KAYLAN, MD, PHD prescribe more brand-name or generic drugs? ▼
Does KERIM KAYLAN, MD, PHD prescribe opioids? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does KERIM KAYLAN, MD, PHD prescribe most often? ▼
Does KERIM KAYLAN, MD, PHD accept Medicare? ▼
How can I verify KERIM KAYLAN, MD, PHD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology